There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Marinus (MRNS), Geron Corp (GERN) and Genmab A/S (GMAB) with bullish sentiments.
H.C. Wainwright analyst Douglas Tsao initiated coverage with a Buy rating on Marinus today and set a price target of $5. The company’s shares closed last Monday at $1.15, close to its 52-week low of $0.77.
“Our thesis for Marinus is based on the following points: 1. We recognize investors’ “wait and see” attitude regarding ganaxolone’s utility in treating psychiatric conditions, such as PPD and treatment resistant depression, but we think the market is overlooking ganaxolone’s utility in treating epilepsy and seizures.”
According to TipRanks.com, Tsao is a 1-star analyst with an average return of -0.7% and a 47.9% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Crinetics Pharmaceuticals Inc, Outlook Therapeutics Inc, and Protagonist Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Marinus with a $4 average price target, representing a 244.8% upside. In a report issued on August 21, Ladenburg Thalmann & Co. also maintained a Buy rating on the stock with a $3 price target.
See today’s analyst top recommended stocks >>
Geron Corp (GERN)
In a report released today, Vernon Bernardino from H.C. Wainwright initiated coverage with a Buy rating on Geron Corp and a price target of $4. The company’s shares closed last Monday at $1.40, close to its 52-week low of $0.95.
“Our $4 PT was derived by using a weighted-average cost of capital of 21% for Geron shares to discount free cash flows from our projection of annual sales of imetelstat in MDS and MF, and dividing them by our projected number of shares for each year to account for the effects of share dilution. Geron ended fiscal 2Q19 with $162.3M in cash and equivalents, which we estimate operationally sufficient into the second half of 2020.”
According to TipRanks.com, Bernardino has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.7% and a 29.7% success rate. Bernardino covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals Inc, Miragen Therapeutics Inc, and Seelos Therapeutics Inc.
Currently, the analyst consensus on Geron Corp is a Strong Buy with an average price target of $4.17.
Genmab A/S (GMAB)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Genmab A/S, with a price target of $24. The company’s shares closed last Monday at $20.38, close to its 52-week high of $21.45.
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -10.7% and a 27.6% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.
Currently, the analyst consensus on Genmab A/S is a Strong Buy with an average price target of $23.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.